Clinical Trial

Study of HS-20105 for Injection in Patients With Advanced Solid Tumors.

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated November 22, 2023 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
HS-20105 is a novel antibody-drug conjugate (ADC) targeting Trop-2. This first-in-human trial is aimed to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to evaluate the pharmacokinetics (PK), safety and preliminary anti-tumor activity of HS-20105 in patients with advanced solid tumors.
Trial Details
NCT Number NCT06144723
Lead Sponsor Hansoh BioMedical R&D Company
Conditions Advanced Solid Tumor
Enrollment 402 participants
Start Date 2024-03-01
Primary Completion 2026-03 (estimated)
Study Completion 2027-03-01 (estimated)
Updated on ClinicalTrials.gov 2023-11-22